7 Apr 2014 11:46
e-Therapeutics announces directorate change
Oxford and Newcastle, UK, 7th April 2014 - e-Therapeutics plc (AIM:ETX) announces that Dr Daniel Elger has resigned as Chief Financial Officer and a Director of e-Therapeutics plc with immediate effect. The Board thanks Dr Elger for his notable contributions to the Company and wishes him the best of luck with future ventures.
In the interim, e-Therapeutics' finances will be managed by Mr Paul Stockdale, who has been the Company's Financial Controller since January 2012. Paul is a Chartered Accountant, and was a Senior Manager at Deloitte before roles in finance and operations management in the charitable and automotive sectors. He took First Class Honours in Natural Sciences at Cambridge. An announcement concerning succession will be made at the appropriate time.
Contacts:
e-Therapeutics plc
Malcolm Young
Tel: +44 (0) 7733 263 513
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Fred Walsh / Duncan Monteith
Tel: +44 (0) 20 7886 2500
www.panmure.com
Instinctif Partners
Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill
Tel: +44 (0) 20 7457 2020
Email: e-therapeutics@instinctif.com
CommStrat Group (US)
Ted Agne
Tel: (+1) 781 631 3117
Email: edagne@comstratgroup.com
About e-Therapeutics
e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.